Opinion ID: 440186
Heading Depth: 2
Heading Rank: 1

Heading: Advertising for Bayer Aspirin.

Text: 8 1. The complaint charged that Sterling had advertised that it was scientifically established that Bayer Aspirin had overall pharmaceutical superiority to other brands and that it was also pharmaceutically superior as to four specific attributes: purity, freshness, stability, and speed of disintegration. 9 The Commission held that the Government had not met its burden of proof on the charge that a study done by Sterling on overall pharmaceutical quality did not demonstrate Bayer's superior quality. However, the Commission held that Sterling's scientific study did not establish superior pharmaceutical quality as to the four specific attributes. 10 2. The complaint charged that Sterling had represented that Bayer's therapeutic effectiveness had been established by scientific means. 11 The Commission found that the representation had been made in the advertising and that the claim was not supported by scientifically acceptable evidence. 12 3. The complaint charged that advertising represented that Bayer relieved nervous tension, stress, fatigue, and depression and that there was no reasonable basis for the claim. 13 The Commission held that the advertising did not make this representation. 14